ReShape Lifesciences Net Worth
ReShape Lifesciences Net Worth Breakdown | RSLS |
ReShape Lifesciences Net Worth Analysis
ReShape Lifesciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including ReShape Lifesciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of ReShape Lifesciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform ReShape Lifesciences' net worth analysis. One common approach is to calculate ReShape Lifesciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares ReShape Lifesciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing ReShape Lifesciences' net worth. This approach calculates the present value of ReShape Lifesciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of ReShape Lifesciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate ReShape Lifesciences' net worth. This involves comparing ReShape Lifesciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into ReShape Lifesciences' net worth relative to its peers.
Enterprise Value |
|
To determine if ReShape Lifesciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding ReShape Lifesciences' net worth research are outlined below:
| ReShape Lifesciences generated a negative expected return over the last 90 days | |
| ReShape Lifesciences has high historical volatility and very poor performance | |
| ReShape Lifesciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 8.68 M. Net Loss for the year was (11.39 M) with profit before overhead, payroll, taxes, and interest of 6.8 M. | |
| ReShape Lifesciences currently holds about 11.49 M in cash with (16.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51. | |
| ReShape Lifesciences has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Disposition of tradable shares by Thomas Stankovich of ReShape Lifesciences at 0.17 subject to Rule 16b-3 |
ReShape Lifesciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in ReShape Lifesciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ReShape Lifesciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 23rd of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know ReShape Lifesciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ReShape Lifesciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ReShape Lifesciences backward and forwards among themselves. ReShape Lifesciences' institutional investor refers to the entity that pools money to purchase ReShape Lifesciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Goldman Sachs Group Inc | 2024-06-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Millennium Management Llc | 2024-06-30 | 0.0 | Vanguard Group Inc | 2024-09-30 | 0.0 | Geode Capital Management, Llc | 2024-09-30 | 0.0 | Xtx Topco Ltd | 2024-09-30 | 0.0 | Two Sigma Securities, Llc | 2024-06-30 | 0.0 | Virtu Financial Llc | 2024-06-30 | 58.9 K | Ubs Group Ag | 2024-06-30 | 57.8 K | Blackrock Inc | 2024-06-30 | 34.1 K | Hrt Financial Llc | 2024-06-30 | 19.6 K |
Follow ReShape Lifesciences' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.64 M.Market Cap |
|
Project ReShape Lifesciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.07) | (1.12) | |
| Return On Capital Employed | (2.13) | (2.23) | |
| Return On Assets | (1.07) | (1.12) | |
| Return On Equity | (1.71) | (1.79) |
When accessing ReShape Lifesciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures ReShape Lifesciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of ReShape Lifesciences' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in ReShape Lifesciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ReShape Lifesciences. Check ReShape Lifesciences' Beneish M Score to see the likelihood of ReShape Lifesciences' management manipulating its earnings.
Evaluate ReShape Lifesciences' management efficiency
ReShape Lifesciences has return on total asset (ROA) of (0.6346) % which means that it has lost $0.6346 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8459) %, meaning that it created substantial loss on money invested by shareholders. ReShape Lifesciences' management efficiency ratios could be used to measure how well ReShape Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.12 in 2024. Return On Capital Employed is likely to drop to -2.23 in 2024. At this time, ReShape Lifesciences' Total Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 4 M in 2024, whereas Other Assets are likely to drop slightly above 111.4 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 64.88 | 61.63 | |
| Tangible Book Value Per Share | 64.88 | 61.63 | |
| Enterprise Value Over EBITDA | 0.19 | 0.20 | |
| Price Book Value Ratio | 0.22 | 0.21 | |
| Enterprise Value Multiple | 0.19 | 0.20 | |
| Price Fair Value | 0.22 | 0.21 | |
| Enterprise Value | -2.7 M | -2.6 M |
The decision-making processes within ReShape Lifesciences are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue 0.4159 | Revenue 8 M | Quarterly Revenue Growth (0.13) | Revenue Per Share 27.638 | Return On Equity (1.85) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ReShape Lifesciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on ReShape Lifesciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ReShape Lifesciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ReShape Lifesciences Corporate Filings
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 17th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 1st of October 2024 Other Reports | ViewVerify | |
13A | 26th of September 2024 An amended filing to the original Schedule 13G | ViewVerify |
ReShape Lifesciences Earnings per Share Projection vs Actual
ReShape Lifesciences Corporate Management
| MBA DVM | VP Officer | Profile | |
| Al Diaz | Vice RD | Profile | |
| DVM DVM | VP Officer | Profile | |
| Thomas Stankovich | Chief Officer | Profile | |
| Jody Dahlman | Director Communications | Profile | |
| Katherine Tweden | CoFounder | Profile |
Additional Tools for ReShape Stock Analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.